Download PDF
Der Klinikarzt 2014; 43(12): 568-573
DOI: 10.1055/s-0034-1399789
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Seltener Tumor mit guter Prognose: das Analkarzinom – Wichtig ist die frühzeitige Diagnose

Rare tumour with good prognosis: anal carcinoma – Early diagnosis is of importance
Johannes Jongen
1   Proktologische Praxis Kiel und Abteilung Proktologische Chirurgie, Park-Klinik, Kiel
,
Jonas Schumacher
1   Proktologische Praxis Kiel und Abteilung Proktologische Chirurgie, Park-Klinik, Kiel
,
Peter Niehoff
2   Klinik für Strahlentherapie Kliniken der Stadt Köln, Klinikum der Universität Witten-Herdecke, Köln
,
Volker Kahlke
1   Proktologische Praxis Kiel und Abteilung Proktologische Chirurgie, Park-Klinik, Kiel
3   Medizinische Fakultät, Christian-Albrechts-Universität zu Kiel, Kiel
› Author Affiliations
Further Information

Publication History

Publication Date:
29 December 2014 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das Analkarzinom ist mit einem Anteil von bis zu 5 % aller Karzinome im Gastrointestinaltrakt ein relativ seltener Tumor mit in den letzten Jahren steigender Inzidenz, der häufig (80–90 %) mit dem humanen Papillomavirus (HPV) assoziiert ist. Histologisch handelt es sich meist um ein Plattenepithelkarzinom. Die Diagnose eines Analrandkarzinoms ist über eine Inspektion und eine digital-rektale Untersuchung relativ einfach zu stellen und bioptisch bzw. über eine Exzision abzusichern. Danach folgen die üblichen Staginguntersuchungen. Kleine, gut differenzierte Analrandkarzinome (pT1 und pT2) und pT1-Analkanalkarzinome, können mit einer R0-Exzision gut behandelt werden, eine engmaschige Nachsorge vorausgesetzt. Alle anderen T-Stadien bedürfen einer kombinierten Radiochemotherapie (RCT). Diese ist schon 40 Jahre etabliert, die Radiotherapie hat sich in den Jahren allerdings zu einer intensitätsmodulierten Strahlentherapie in Kombination mit einer Brachytherapie „verfeinert“. Nach wie vor Standard ist die Chemotherapie mit Mitomycin C und 5-Fluorouracil. Abhängig vom Stadium ist die Therapie also in Zusammenarbeit mit dem Strahlenonkologen zu koordinieren. Unter diesen Bedingungen ist das Analkarzinom ein Tumor, der mit einer guten Prognose und dem Erhalt der Kontinenz verbunden ist.

Summary

Anal carcinoma is a rare tumour (less than 5 % of all gastrointestinal cancers) that is often associated with the human papilloma virus (HPV). Incidence is increasing. Most anal cancers are squamous cell carcinomas. Diagnosis is easy by inspection (anal margin) or rectal examination/anoscopy (anal canal). Biopsy or excision of the tumour confirms the diagnosis. Staging includes the common staging procedures. Small, well differentiated anal margin carcinomas (pT1 and pT2) can be excised (R0), but a close follow up of the patient is necessary. Very small anal canal carcinomas (pT1) might also be treated by surgery alone. All other T-stages or tumours with unknown localization and/or resection status should be treated by combined radiochemotherapy (RCT). RCT has been the standard for the last 40 years. In this time differentiated radiotherapy treatments have been developed: three-field percutaneous therapy, RCT in combination with interstitial brachytherapy. Chemotherapy with mitomycine-C and 5-fluorouracil has remained the standard. Therefore therapy should be stage dependent and in cooperation with the oncologist/radiotherapist. Under these conditions anal carcinoma is a tumour with a good prognosis and a good quality of life after therapy (no abdominoperineal resection/no colostomy needed in most cases).

Key words

Anal carcinoma - human papilloma virus (HPV) - diagnosis - combined radiochemotherapy (RCT) - brachytherapy - rectal excision - prognosis
 

  • Literatur

  • 1 Wilkinson JR, Morris EJ, Downing A et al. The rising incidence of anal cancer in England 1990–2010: a population-based study. Colorectal Dis 2014; 16: O234-O239
    CrossrefPubMedGoogle Scholar
  • 2 Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet 2013; 382: 889-899
    CrossrefPubMedGoogle Scholar
  • 3 Palefsky J. Human papillomavirus and anal neoplasia. Curr HIV/AIDS Rep 2008; 5: 78-85
    CrossrefPubMedGoogle Scholar
  • 4 Albright JB, Bonatti H, Stauffer J et al. Colorectal and anal neoplasms following liver transplantation. Colorectal Dis 2010; 12: 657-666
    PubMedGoogle Scholar
  • 5 AWMF-Leitlinie: Anale Dysplasien und Analkarzinome bei HIV-Infizierten: Prävention, Diagnostik und Therapie. www.awmf.org/leitlinien/detail/ll/055–007.html (zuletzt am 18.06.2014)
    PubMedGoogle Scholar
  • 6 Edgren G, Sparén P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol 2007; 8: 311-316
    CrossrefPubMedGoogle Scholar
  • 7 Parikh J, Shaw A, Grant LA et al. Anal carcinomas: the role of endoanal ultrasound and magnetic resonance imaging in staging, response evaluation and follow-up. Eur Radiol 2011; 21: 776-785
    CrossrefPubMedGoogle Scholar
  • 8 Steele SR, Varma MG, Melton GB et al. Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Pracitce parameters for anal squamous neoplasms. Dis Colon Rectum 2012; 55: 735-749
    CrossrefPubMedGoogle Scholar
  • 9 Kronfli M, Glynne-Jones R. Chemoradiotherapy in anal cancer. Colorectal Dis 2011; 13 (Suppl 1): 33-38
    CrossrefPubMedGoogle Scholar
  • 10 Glynne-Jones R, Nilsson PJ, Aschele C et al. Anal Cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl 3): iii 10-20
    CrossrefPubMedGoogle Scholar
  • 11 Giani I, Mistrangelo M, Fucini C. Italian Society of Colo-Rectal Surgery. The treatment of squamous anal carcinoma: guidelines of the Italian Society of Colo-Rectal Surgery. Tech Coloproctol 2013; 17: 171-179
    CrossrefPubMedGoogle Scholar
  • 12 Fraunholz IB, Haberl A, Klauke S et al. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease. Dis Colon Rectum 2014; 57: 423-431
    CrossrefPubMedGoogle Scholar
  • 13 Nigro ND, Vaitkevicius VK, Considine BJr. Combined therapy for cancer of the anal canal: a preliminary report. 1974. Dis Colon Rectum 1993; 36: 709-711
    CrossrefPubMedGoogle Scholar
  • 14 Fuchshuber PR, Rodriguez-Bigas M, Weber T, Petrelli NJ. Anal canal and perianal epidermoid cancers. J Am Coll Surg 1997; 185: 494-505
    CrossrefPubMedGoogle Scholar
  • 15 James RD, Glynne-Jones R, Meadows HM et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol 2013; 14: 516-524
    CrossrefPubMedGoogle Scholar
  • 16 Doyen J, Benezery K, Follana P et al. Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy. Dis Colon Rectum 2013; 56: 1125-1133
    CrossrefPubMedGoogle Scholar
  • 17 Mazeron JJ, van Limbergen E. Anorectal cancer. In: Gerbaulet A, Pötter R, Mazeron J. et al (eds.). The GEC-ESTRO Handbook of Brachytherapy. Brussels: ESTRO; 2000: 505514
    Google Scholar
  • 18 Hallemeier CL, You YN, Larson DW et al. Multimodality therapy including salvage surgical resection and intraoperative radiotherapy for patients with squamous-cell carcinoma of the anus with residual or recurrent disease after primary chemoradiotherapy. Dis Colon Rectum 2014; 57: 442-448
    CrossrefPubMedGoogle Scholar
  • 19 Vordermark D, Sailer M, Flentje M et al. Curative-intent radiation therapy in anal carcinoma: quality of life and sphincter function. Radiother Oncol 1999; 52: 239-243
    CrossrefPubMedGoogle Scholar
  • 20 Andreyev HJ, Davidson SE, Gillespie C et al. Britisch Society of Gastroenterology: Association of Colo-Proctology of Great Britain and Ireland; Association of Upper Gastrointestinal Surgeons; Faculty of Clinical Oncology Section of the Royal College of Radiologists. Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut 2012; 61: 179-192
    CrossrefPubMedGoogle Scholar